Download PDF
Adipositas - Ursachen, Folgeerkrankungen, Therapie 2009; 03(03): 133-136
DOI: 10.1055/s-0037-1618677
Adipositas und Lipidstoffwechselstörungen
Schattauer GmbH

Lipide und Lipoproteine bei Adipositas und bei Gewichtsreduktion

Effects of obesity and weight-reduction on plasma lipids and lipoproteins
J. G. Wechsler
1   Abteilung Innere Medizin, Krankenhaus Barmherzige Brüder München
› Author Affiliations
Further Information

Publication History

Publication Date:
22 December 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Bei Adipositas finden sich erhöhte Triglyzerid- spiegel und niedrige HDL-Cholesterin-Konzentrationen.

Trotz Adipositas sind Serumcholesterin-und LDL-Cholesterin-Konzentrationen oft normal. Erfolgreiche Gewichtsreduktion führt zu einer Verbesserung dieser Dyslipoproteinämie, unabhängig von der angewandten Therapie (Diät, VLCD, Medikamente, Adipositaschirurgie). Die Konzentration der AOPPs (Advanced Oxidation Protein Products) fällt unter Gewichtsreduktion signifikant ab. Erfolgreiche Adipositastherapie senkt das Risiko für kardiovaskuläre Erkrankungen durch Senkung der Lipid-, Lipoprotein- und AOPPs-Konzentrationen.

Summary

Hyperlipoproteinemia and dyslipoproteinemia in obese persons is characterized by elevated fasting triglycerides and decreased HDL-cholesterol-levels.

Total cholesterol- and LDL-cholesterol-levels are quite normal in comparison with normalweight people.

Successful weight-reduction induced an improvement of dyslipoproteinemia independent of the applied treatment method (diet, VLCD, drugs, surgery).

The concentration of advanced oxidation protein products (AOPPs) felt down during weight-reduction significantly.

Obesity treatment reduces the risk for coronary and vascular events lowering lipids and lipoproteins and AOPPs.

Schlüsselwörter

Adipositas - Lipide - Lipoproteine - Gewichtsreduktion

Keywords

Obesity - lipids - lipoproteins - weight-reduction
 

  • Literatur

  • 1 Anderson JW, Konz EC. Obesity and Disease Management: Effects of weight loss on comorbid conditions. Obes Res 2001; 09: 326S-334S.
    CrossrefPubMedGoogle Scholar
  • 2 Anderson JW. et al. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr 2001; 74: 579-584.
    CrossrefPubMedGoogle Scholar
  • 3 Brinkworth GD. et al. Long-term effects of a verylow-carbohydrate weight loss diet compared with a isocaloric low-fat diet after 12 mo. Am J Clin Nutr 2009; 90: 23-32.
    CrossrefPubMedGoogle Scholar
  • 4 Brolin RE. et al. Lipid risk profile and weight stability after gastric restrictive operations for morbid obesity. J Gastrointest Surg 2000; 04: 464-469.
    CrossrefPubMedGoogle Scholar
  • 5 Després JP. et al. Effect of rimonabant on the hightriglyceride/ low HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: The ADAGIO-lipids trial. Arterioscler Thromb Vasc Biol 2009; 29: 416-423.
    CrossrefPubMedGoogle Scholar
  • 6 Dixon JB, O’Brien PE. Lipid profile in the severely obese: changes with weight loss after lap-band surgery. Obes Res 2002; 10: 903-910.
    CrossrefPubMedGoogle Scholar
  • 7 Hong K. et al. Analysis of weight loss outcomes using VLCD in black and white overweight and obese women with and without metabolic syndrome. International Journal of Obesity 2005; 29: 436-442.
    CrossrefPubMedGoogle Scholar
  • 8 Imaguire C. Langzeitergebnisse eines interdisziplinären Adipositas-Therapieprogrammes. Dissertation TU München. 2005
    PubMedGoogle Scholar
  • 9 Krzystek-Korpacka M. et al. Advanced oxidation protein products (AOPPs) in juvenile overweight and obesity prior to and following weight reduction. Clincial Biochemistry 2008; 41: 943-949.
    PubMedGoogle Scholar
  • 10 LABS Consortium. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009; 361: 445-454.
    CrossrefPubMedGoogle Scholar
  • 11 Rucker D. et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 1194-1199.
    CrossrefPubMedGoogle Scholar
  • 12 Robinson KM. Surgical treatment of obesity – weighing the facts. N Engl J Med 2009; 361: 520-521.
    CrossrefPubMedGoogle Scholar
  • 13 Simonen P, Gylling H, Miettinen TA. Acute effects of weight reduction on cholesterol metabolism in obese type 2 diabetes. Clinica Chimica Acta 2002; 316: 55-61.
    CrossrefPubMedGoogle Scholar
  • 14 Sjöström L. et al. Effects of bariatric surgery on mortality in swedish obese subjects. N Engl J Med 2007; 357: 741-752.
    CrossrefPubMedGoogle Scholar
  • 15 Sjöström L. et al. Diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683-2693.
    CrossrefPubMedGoogle Scholar
  • 16 Suchanek P. et al. Changes of plasma lipids during weight reduction in females depends on AOPA5 variants. Ann Nutr Metab 2008; 53: 104-108.
    CrossrefPubMedGoogle Scholar
  • 17 Van Hees A. et al. Fasting and postprandial remnantlike particle cholesterol concentrations in obese participants are associated with plasma triglycerides, insulin resistance, and body fat distribution. J Nutr 2008; 138: 2399-2405.
    CrossrefPubMedGoogle Scholar
  • 18 Vila M. et al. Changes in lipid profile and insulin resistance in obese patients after Scopinaro biliopancreatic diversion. Obes Surg 2009; 19: 299-306.
    CrossrefPubMedGoogle Scholar
  • 19 Wechsler JG. Hyperlipoproteinämie. Hrsg. H. Kaffarnik und J. Schneider, Marburg. Perimed Fachbuch-Verlagsgesellschaft 1984; 102-108.
    PubMedGoogle Scholar
  • 20 Wechsler JG. Diätetische Therapie der Adipositas. Deutsches Ärzteblatt 1997; 36: A2250-A2256.
    PubMedGoogle Scholar
  • 21 Wechsler JG. Stellenwert der Ernährung bei Adipositas. Internist 2007; 48: 1093-1100.
    CrossrefPubMedGoogle Scholar